Cancer feature: cnaPANCAN235

ACAT2 AGPAT4 ARID1B C6orf118 C6orf120 C6orf123 C6orf99 CCR6 CLDN20 CNKSR3 DACT2 DLL1 DYNLT1 ERMARD EZR FAM120B FGFR1OP FNDC1 FRMD1 GPR31 GTF2H5 IGF2R IPCEF1 KIF25 LPA MAP3K4 MAS1 MLLT4 MPC1 MRPL18 NOX3 OPRM1 PACRG PARK2 PDCD2 PDE10A PHF10 PLG PNLDC1 PRR18 PSMB1 QKI RGS17 RNASET2 RP11-514O12.4 RPS6KA2 RSPH3 SCAF8 SERAC1 SFT2D1 SLC22A1 SLC22A2 SLC22A3 SMOC2 SNX9 SOD2 SYNJ2 SYTL3 T TAGAP TBP TCP1 TCP10 TCP10L2 TCTE3 TFB1M THBS2 TIAM2 TMEM181 TMEM242 TTLL2 TULP4 UNC93A WDR27 WTAP ZDHHC14

Known Driver Genes: None

Copy number alternation: loss

CDK9_5576

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer